Biosceptre International is a public, unlisted biotechnology company based in Cambridge, UK. Biosceptre is developing and commercializing antibody technologies to address a wide range of applications in the treatment of cancer. P2X7 is a major cellular receptor with a significant role in apoptosis. Our technology is based on the fundamental discovery of a conformationally distinct variant of P2X7 that is highly specific to cancer cells but not on normal cells, and broadly occurring across a range of cancers. Biosceptre has developed and patented a number of immune oncological therapeutics that are in and entering the clinic and that bind to nfP2X7 (the "non-functional" form of P2X7) on cancer cells, but not to normal P2X7, offering the potential for significant advancement in the treatment of a broad range of cancers.